Home/Acumen Pharmaceuticals/Jasna Jerecic, PhD
JJ

Jasna Jerecic, PhD

Disease Area Strategy Lead

Acumen Pharmaceuticals

Acumen Pharmaceuticals Pipeline

DrugIndicationPhase
Sabirnetug (ACU193) - Intravenous (IV)Early Alzheimer's DiseasePhase 2
Sabirnetug (ACU193) - Subcutaneous (SC)Early Alzheimer's DiseasePhase 1
Enhanced Brain Delivery (EBD™) [TfR-Brain transporter + AβO mAb]Early Alzheimer's DiseasePreclinical